Clinical, immunophenotypic and cytogenetic profile of acute lymphoblastic leukemia in children aged 1–12 years at a tertiary care centre in central India: a prospective observational study
DOI:
https://doi.org/10.18203/2349-3291.ijcp20261895Keywords:
Acute lymphoblastic leukemia, Cytogenetic profile, Immunophenotypic, Pediatric oncologyAbstract
Background: Acute leukemias, particularly ALL, constitute one of the most common and curable malignancies in children across India. Their heterogeneity mandates detailed evaluation of clinical, immunophenotypic and cytogenetic features to guide therapy and prognostication. Indian studies highlight variable survival, with rural populations often disadvantaged in access and outcomes.
Methods: We conducted a two-year prospective study (2022–2024) at a tertiary center in central India to assess the clinical, immunophenotypic and cytogenetic profile of children (1–12 years) with newly diagnosed ALL. The study compared clinical features, immunophenotypic subtypes and cytogenetic abnormalities between patients with poor outcomes and others to improve diagnostic accuracy, risk stratification and treatment planning in resource-limited settings.
Results: This study evaluated 40 pediatric patients with ALL to identify factors influencing clinical outcomes. B-cell ALL was the predominant subtype (82.5%) and was associated with better outcomes compared to T-cell ALL. Extremes of age (<3 years and >10 years), high total leukocyte count (>50,000/µl), severe thrombocytopenia and high-risk stratification were significantly associated with poorer outcomes. Immunophenotypic markers suggestive of T-cell lineage and unfavourable cytogenetic abnormalities such as t (9;22) were linked to poorer prognosis, while t (12;21) was associated with favorable outcomes. Overall, only 40% of patients achieved remission, highlighting the need for early risk stratification and close monitoring of high-risk children.
Conclusions: Immunophenotypic and cytogenetic profiles significantly influenced patient outcomes. Specifically, T-cell markers (CD3, CD5, CD7) and unfavorable translocations like t (9;22) or t (1;19) were associated with a poor prognosis. Conversely, B-cell markers (CD19, CD10) and the t (12;21) translocation predicted more favorable results. Although the cohort was stratified into standard (22.5%), intermediate (65%) and high-risk (22.5%) groups, the trend linking high-risk status to poorer outcomes was not statistically significant, likely due to the small sample size.
References
Lanzkowsky P, Lipton J, Fish JD. Lanzkowsky's manual of pediatric hematology and oncology. Elsevier; 2016.
Nathan DG, Oski FA, Orkin SH, Fisher DE, editors. Nathan and Oski’s hematology and oncology of infancy and childhood. Eighth edition. Philadelphia, PA: Elsevier, Saunders. 2015.
Behrman RE, Nelson WE, Kliegman R, Jenson HB. Nelson textbook of pediatrics. Elsevier Brasil. 1992.
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–55.
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in childhood acute lymphoblastic leukemia. Haematologica. 2014;99:104–11.
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–78.
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52.
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18–24.
Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–43.
Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:7–12.
Nachman JB, Sather HN, Sensel MG. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia. J Clin Oncol. 1998;16(3):920–30.
Moorman AV, Harrison CJ, Buck GA. Karyotype is an independent prognostic factor in acute lymphoblastic leukemia. Blood. 2007;109(8):3189–97.
Panda SP, Mallick B, Dash M, Samal P, Mishra SK, Panda SS. Clinical profile and outcomes of acute lymphoblastic leukaemia in children; an experience from a newly established pediatric oncology unit from eastern zone of India. Int J Sci Res. 2018;7(7):365.
Lee JW, Cho B. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean J Pediatr. 2017;60(5):129-37.
Siddaiahgari SR, Awaghad MA, Latha MS. Clinical, hematological and cytogenetic profile of acute lymphoblastic leukemia in children. J Clin Diagn Res. 2015;9(10):5–8.
Pandian G, Sankarasubramanian ML. Clinical and immunophenotypic patterns in pediatric acute leukemias. Int J Contemp Pediatr. 2018;5(4):1183–8.
Lingayat A, Totala P, Ukey S, Farookh A. Clinical profile, complications and outcome of leukemia in children. Indian J Med Paediatr Oncol. 2019;40(3):93–9.
Asthana S, Labani S, Mehrana S, Bakhshi S. Incidence of childhood leukemia and lymphoma in India. Pediatr Hematol Oncol J. 2018;3(4):115–20.
Ba-Saddik IA. Childhood cancer in Aden, Yemen. Cancer Epidemiol. 2013;37(6):803–6.
Mousavi SM, Pourfeizi A, Dastgiri S. Childhood cancer in Iran. J Pediatr Hematol Oncol. 2010;32(5):376–82.
Al-Sheyyab M, Bateiha A, El Kayed S, Hajjawi B. Incidence of childhood cancer in Jordan. Ann Saudi Med. 2003;23(5):260–3.
Bishop K, Hanchard B, Gibson T. Incidence of childhood cancer in Jamaica. West Indian Med J. 2014;62(7):45.
Downloads
Published
How to Cite
Issue
Section
